Why the study?
Human iPSC-derived cardiomyocytes have transitioned from research laboratories to widespread preclinical safety evaluation, motivating a review of their toxicology applications for hazard assessment and risk characterization.
Human iPSC-derived cardiomyocytes offer a promising in vitro model for cardiotoxicity hazard identification and risk characterization, especially for non-pharmaceutical chemicals.
Answers are grounded in this paper and cite their sources.
Supports integration of iPSC-cardiomyocyte assays into preclinical screening; extends validation for accurate hazard identification across drugs and chemicals.
INTRODUCTION: Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes is one of the most widely used cell-based models that resulted from the discovery of how non-embryonic stem cells can be differentiated into multiple cell types. In just one decade, iPSC-derived cardiomyocytes went from a research lab to widespread use in biomedical research and preclinical safety evaluation for drugs and other chemicals. AREAS COVERED: This manuscript reviews data on toxicology applications of human iPSC-derived cardiomyocytes. We detail the outcome of a systematic literature search on their use (i) in hazard assessment for cardiotoxicity liabilities, (ii) for risk characterization, (iii) as models for population variability, and (iv) in studies of personalized medicine and disease. EXPERT OPINION: iPSC-derived cardiomyocytes are useful to increase the accuracy, precision, and efficiency of cardiotoxicity hazard identification for both drugs and non-pharmaceuticals, with recent efforts beginning to demonstrate their utility for risk characterization. Notable limitations include the needs to improve the maturation of cells in culture, to better understand their potential use identifying structural cardiotoxicity, and for additional case studies involving population-wide and disease-specific risk characterization. Ultimately, the greatest future benefits are likely for non-pharmaceutical chemicals, filling a critical gap where no routine testing for cardiotoxicity is currently performed.
No takes yet. Share an insight, caveat, or question.
Burnett et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: